Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China

Peng Men,1,2 Tianbi Liu,1,3 Suodi Zhai1,2 1Department of Pharmacy, Peking University Third Hospital, Beijing, People’s Republic of China; 2Institute for Drug Evaluation, Peking University Health Science Center, Beijing, People’s Republic of China; 3Department of Pharmacy Administ...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Men P, Liu T, Zhai S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	diabetes china sodium-glucose transporter 2 inhibitors cost-effectiveness Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/6daeb1e86f94447fb0247f4365e0414e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6daeb1e86f94447fb0247f4365e0414e
record_format	dspace
spelling	oai:doaj.org-article:6daeb1e86f94447fb0247f4365e0414e2021-12-02T12:28:02ZEmpagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China1178-7007https://doaj.org/article/6daeb1e86f94447fb0247f4365e0414e2020-08-01T00:00:00Zhttps://www.dovepress.com/empagliflozin-in-type-2-diabetes-mellitus-patients-with-high-cardiovas-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Peng Men,1,2 Tianbi Liu,1,3 Suodi Zhai1,2 1Department of Pharmacy, Peking University Third Hospital, Beijing, People’s Republic of China; 2Institute for Drug Evaluation, Peking University Health Science Center, Beijing, People’s Republic of China; 3Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, People’s Republic of ChinaCorrespondence: Suodi Zhai Department of Pharmacy, Peking University Third Hospital, No. 49 North Huayuan Road, Haidian District, Beijing, People’s Republic of ChinaTel +86-13401169143Fax +86-10-82266686Email zhaisuodi@163.comPurpose: To evaluate the cost-utility of empagliflozin, in addition to best available standard care (BASC), for the treatment of adult patients with T2DM at high cardiovascular risk from the Chinese healthcare system perspective.Methods: A Microsoft Excel-based patient-level simulation model, based on the EMPA-REG OUTCOME trial data, was adapted and used to project individual’s clinical and economic outcomes over a lifetime horizon. The cost and utility values were derived from databases and published studies. Numbers and rates of diabetes-related events, life-years (LYs), quality-adjusted life-years (QALYs), costs (¥ 2019) as well as incremental cost-utility ratios (ICURs) were calculated. Deterministic and probabilistic sensitivity analyses were conducted to test the robustness of the model results.Results: Compared with BASC, empagliflozin plus BASC was predicted to result in an additional 1.01 QALYs (8.05 QALYs vs 7.04 QALYs) at an incremental cost of ¥ 4002 per patient. The modeled ICUR was ¥ 3988 per QALY gained, which was considered highly cost-effective in China compared to both one and three times the GDP per capita in 2019 (¥ 70,892 and ¥ 212,676). The deterministic and probabilistic sensitivity analyses confirmed the robustness of base-case results.Conclusion: This is the first cost-utility analysis regarding the use of empagliflozin in patients with T2DM in China, the world’s most affected country by the T2DM pandemic. The economic evaluation suggests that empagliflozin added to BASC was estimated to be a highly value-for-money option for the treatment of adult patients with T2DM at high cardiovascular risk in the Chinese healthcare setting.Keywords: diabetes, China, sodium-glucose transporter 2 inhibitors, cost-effectivenessMen PLiu TZhai SDove Medical Pressarticlediabeteschinasodium-glucose transporter 2 inhibitorscost-effectivenessSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 13, Pp 2823-2831 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	diabetes china sodium-glucose transporter 2 inhibitors cost-effectiveness Specialties of internal medicine RC581-951
spellingShingle	diabetes china sodium-glucose transporter 2 inhibitors cost-effectiveness Specialties of internal medicine RC581-951 Men P Liu T Zhai S Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China
description	Peng Men,1,2 Tianbi Liu,1,3 Suodi Zhai1,2 1Department of Pharmacy, Peking University Third Hospital, Beijing, People’s Republic of China; 2Institute for Drug Evaluation, Peking University Health Science Center, Beijing, People’s Republic of China; 3Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, People’s Republic of ChinaCorrespondence: Suodi Zhai Department of Pharmacy, Peking University Third Hospital, No. 49 North Huayuan Road, Haidian District, Beijing, People’s Republic of ChinaTel +86-13401169143Fax +86-10-82266686Email zhaisuodi@163.comPurpose: To evaluate the cost-utility of empagliflozin, in addition to best available standard care (BASC), for the treatment of adult patients with T2DM at high cardiovascular risk from the Chinese healthcare system perspective.Methods: A Microsoft Excel-based patient-level simulation model, based on the EMPA-REG OUTCOME trial data, was adapted and used to project individual’s clinical and economic outcomes over a lifetime horizon. The cost and utility values were derived from databases and published studies. Numbers and rates of diabetes-related events, life-years (LYs), quality-adjusted life-years (QALYs), costs (¥ 2019) as well as incremental cost-utility ratios (ICURs) were calculated. Deterministic and probabilistic sensitivity analyses were conducted to test the robustness of the model results.Results: Compared with BASC, empagliflozin plus BASC was predicted to result in an additional 1.01 QALYs (8.05 QALYs vs 7.04 QALYs) at an incremental cost of ¥ 4002 per patient. The modeled ICUR was ¥ 3988 per QALY gained, which was considered highly cost-effective in China compared to both one and three times the GDP per capita in 2019 (¥ 70,892 and ¥ 212,676). The deterministic and probabilistic sensitivity analyses confirmed the robustness of base-case results.Conclusion: This is the first cost-utility analysis regarding the use of empagliflozin in patients with T2DM in China, the world’s most affected country by the T2DM pandemic. The economic evaluation suggests that empagliflozin added to BASC was estimated to be a highly value-for-money option for the treatment of adult patients with T2DM at high cardiovascular risk in the Chinese healthcare setting.Keywords: diabetes, China, sodium-glucose transporter 2 inhibitors, cost-effectiveness
format	article
author	Men P Liu T Zhai S
author_facet	Men P Liu T Zhai S
author_sort	Men P
title	Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China
title_short	Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China
title_full	Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China
title_fullStr	Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China
title_full_unstemmed	Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China
title_sort	empagliflozin in type 2 diabetes mellitus patients with high cardiovascular risk: a model-based cost-utility analysis in china
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/6daeb1e86f94447fb0247f4365e0414e
work_keys_str_mv	AT menp empagliflozinintype2diabetesmellituspatientswithhighcardiovascularriskamodelbasedcostutilityanalysisinchina AT liut empagliflozinintype2diabetesmellituspatientswithhighcardiovascularriskamodelbasedcostutilityanalysisinchina AT zhais empagliflozinintype2diabetesmellituspatientswithhighcardiovascularriskamodelbasedcostutilityanalysisinchina
_version_	1718394458776535040

Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China

Ejemplares similares